Search Results - "Colucci, Philomena"

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study by Zwicker, Jeffrey I, Paranagama, Dilan, Lessen, David S, Colucci, Philomena M, Grunwald, Michael R

“…Polycythemia vera (PV) is associated with increased risk of thrombosis and hemorrhage. Aspirin, recommended for primary thromboprophylaxis, is often combined…”
Get full text

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data by Paranagama, Dilan, Colucci, Philomena, Evans, Kristin A, Bonafede, Machaon, Parasuraman, Shreekant

“…Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic…”
Get full text

Abstract CT236: A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy by Kuykendall, Andrew T., Burke, Lea, Lakshminarayanan, Mani, Colucci, Philomena

“…Abstract Background: Ruxolitinib (JAK1/JAK2 inhibitor) and fedratinib (JAK2/FLT3 inhibitor) are indicated in the US for myelofibrosis (MF); however, some…”
Get full text

Comparison of healthcare utilization and direct costs in three degenerative dementias by Murman, Daniel L, Chen, Qin, Colucci, Philomena M, Colenda, Christopher C, Gelb, Douglas J, Liang, Jersey

“…The authors conducted a survey of healthcare utilization in three dementia syndromes to determine whether type of dementia influenced utilization or resulting…”
Get more information

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A US Real-World Retrospective Cohort Study by Parasuraman, Shreekant, Teschemaker, Anna, Kish, Jonathan K., Savill, Kristin M., Colucci, Philomena

Get full text

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data by Yu, Jingbo, Kish, Jonathan K., Paranagama, Dilan, Colucci, Philomena

“…Introduction Myelofibrosis (MF) is a chronic myeloproliferative neoplasm frequently associated with debilitating disease-related symptoms and shortened overall…”
Get full text

Colorectal polyps by Colucci, Philomena M, Yale, Steven H, Rall, Christopher J

Get full text

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients by Verstovsek, Srdan, Gotlib, Jason, Vannucchi, Alessandro M., Rambaldi, Alessandro, Reiter, Andreas, Shomali, William, George, Tracy I., Patel, Jay L., Colucci, Philomena, Zhen, Huiling, Oliveira, Natalia, Kiladjian, Jean-Jacques

Get full text

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL) by Zwicker, Jeffrey I., Lessen, David S., Colucci, Philomena, Paranagama, Dilan, Grunwald, Michael R.

“…Background Polycythemia vera (PV) is associated with an increased risk of thrombosis and major hemorrhage. Aspirin (ASA) is recommended for primary…”
Get full text

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study by Kvasnicka, Hans Michael, Thiele, Juergen, Bueso-Ramos, Carlos E., Colucci, Philomena, Paranagama, Dilan, Verstovsek, Srdan

“…Background The oral Janus kinase (JAK) 1/JAK2 inhibitor RUX has been shown to induce a reduction in bone marrow (BM) fibrosis in patients (pts) with…”
Get full text

Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study by Gerds, Aaron T., Lyons, Roger M., Colucci, Philomena, Kalafut, Patricia, Paranagama, Dilan, Verstovsek, Srdan

“…Introduction: Myelofibrosis (MF) is a chronic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by progressive bone marrow (BM)…”
Get full text

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea by Altomare, Ivy, Nguyen, Anna, Parasuraman, Shreekant, Paranagama, Dilan, Kish, Jonathan K., Lord, Kevin, Colucci, Philomena

“…Background Polycythemia vera (PV) is a myeloproliferative neoplasm affecting >100,000 people in the United States annually. Patients (pts) with PV are at risk…”
Get full text

REVEAL: Characteristics of Patients with Polycythemia Vera Who Were Diagnosed within 6 Months of Enrollment by Gerds, Aaron T., Altomare, Ivy, Colucci, Philomena, Paranagama, Dilan, Burke, John M

“…Background Polycythemia vera (PV), characterized by erythrocytosis and JAK2 mutations, is associated with increased morbidity and mortality. Patients (pts) are…”
Get full text

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study by Ritchie, Ellen K., Al-Janadi, Anas, Colucci, Philomena, Kalafut, Patricia, Paranagama, Dilan, Mesa, Ruben A.

“…Introduction: ET is a chronic myeloproliferative neoplasm (MPN) characterized by thrombocytosis and an increased risk for thrombotic and hemorrhagic events. ET…”
Get full text

Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea by Altomare, Ivy, Parasuraman, Shreekant, Paranagama, Dilan, Kish, Jonathan, Lord, Kevin, Yu, Jingbo, Colucci, Philomena

“…•About 1 in 4 patients with polycythemia vera become resistant and/or intolerant to hydroxyurea.•Ruxolitinib is the only FDA-approved polycythemia vera…”
Get full text

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group by Shomali, William, Colucci, Philomena, George, Tracy I., Kiladjian, Jean-Jacques, Langford, Cheryl, Patel, Jay L., Reiter, Andreas, Vannucchi, Alessandro M., Gotlib, Jason

Get full text

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1) by Gotlib, Jason, Kiladjian, Jean-Jacques, Vannucchi, Alessandro, Rambaldi, Alessandro, Reiter, Andreas, Shomali, William, George, Tracy I., Patel, Jay L., Colucci, Philomena, Walker, Chris, Zhen, Huiling, Verstovsek, Srdan

“…▪ Background: MLN FGFR1 comprise rare hematologic neoplasms belonging to the World Health Organization major category of fusion tyrosine kinases typically…”
Get full text

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study by Talpaz, Moshe, Prchal, Josef, Afrin, Lawrence, Arcasoy, Murat, Hamburg, Solomon, Clark, Jason, Kornacki, Deanna, Colucci, Philomena, Verstovsek, Srdan

“…•Patients with myelofibrosis and low platelet counts received ruxolitinib•Ruxolitinib was initiated at 5 mg BID and could be titrated up to 15 mg BID•52 of 66…”
Get full text

Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study by Al-Janadi, Anas, Mesa, Ruben A., Colucci, Philomena, Parasuraman, Shreekant, Paranagama, Dilan Chamikara, Grunwald, Michael Richard

“…Introduction: Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms. Guidelines support the use of…”
Get full text

Disease Characteristics of Minority Patient Populations with Polycythemia Vera: An Analysis from the Reveal Study by Altomare, Ivy, Colucci, Philomena, Parasuraman, Shreekant, Paranagama, Dilan Chamikara, Al-Janadi, Anas

“…Introduction: Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. Few…”
Get full text